About Pionyr Immunotherapeutics
Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.
The company was founded in 2015 by Max Krummel, Ph.D., a professor at University of California, San Francisco School of Medicine (UCSF), who has been making significant strides in immuno-oncology since the mid-1990s. Dr. Krummel is the co-inventor of YERVOY® (ipilimumab), the first checkpoint inhibitor, which was approved in 2011 to treat melanoma. Pionyr has exclusively licensed technology from UCSF based on Dr. Krummel’s work.
$1.3M Series A Funding
$8M Series A-1 OrbiMed, SV, Osage, Mission Bay
4 TME-Targeted mABs in Process
Located at MBC BioLabs
$69M Series B NEA, Sofinnova, Vida, Trinitas + Prior Investors
New Labs at Genesis Towers, 40+ Employees
PY314 and PY159 into P1
Pionyr's Third Program
Steven P. James
President and CEO
Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Mr. James is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Allakos Inc and Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).
Kevin P. Baker, PhD
Senior Vice President and Chief Development Officer
Kevin Baker joined Pionyr in 2018. He leads research, nonclinical development, and project management. Dr. Baker has over 30 years of research and development experience, including more than 25 years in the biopharmaceutical industry. Prior to joining Pionyr, he was Senior Vice President of Development Sciences at Five Prime Therapeutics, where he oversaw the nonclinical development and manufacturing for all of FivePrime’s clinical programs. Prior to FivePrime, Dr. Baker was Associate Director at Human Genome Sciences (HGS) where he ran a research team focused on receptor-ligand interactions in the immune system, as well as the project team lead for Belimumab, a monoclonal antibody directed against BLyS BAFF Belimumab is currently marketed for the treatment of SLE (lupus).
Prior to Human Genome Sciences, Dr. Baker was a scientist leading a research lab in the molecular biology group at Genentech and was responsible for identifying, cloning and functional analysis of novel secreted proteins including receptor tyrosine kinases and DNases. Dr. Baker holds a PhD in microbial genetics and molecular biology from the University of Dundee, Scotland, and performed postdoctoral studies in cell biology at the Biozentrum in the University of Basel, Switzerland.
Senior Director, Information Technology
Tony Brew joined Pionyr Immunotherapeutics in June 2021 as Head of Information Technology and Senior Director. Prior to Pionyr, he served as a senior level technology, security and regulatory compliance consultant to life sciences companies in Boston, Philadelphia, and San Francisco Bay Area. Mr. Brew has also served as Senior Director and Head of Information Technology and Security at Hyperion Therapeutics, Horizon Pharma and in senior technology leadership positions as Senior Director of Information Technology and Security at CTI BioPharma, Tercica, Inc and Ipsen in the San Francisco Bay Area and Seattle. In these roles, he optimized technology resources and supported the successful launch of several FDA-approved commercial products in the US and EU. In addition to his extensive technology, information security and regulatory compliance experience, Mr. Brew attended St. Augustine’s College and graduated in Mathematics, Physics & Chemistry, and is also a Certified Network Engineer (CNE), Certifed Messaging Engineer (CME), and Certified Network Administrator (CNA).
Marc Chamberlain, MD
Senior Medical Director
Prior to joining Pionyr, Marc Chamberlain was Medical Director at SystImmune, Inc where he developed protocols for novel multi-valent monoclonal antibodies for first in human early phase clinical trials. Before that, he served as Medical Director at Seattle Genetics following its acquisition of Cascadian Therapeutics, where he led clinical stage development of a novel HER2 tyrosine kinase inhibitor, tucatinib, through clinical proof of concept in HER2 positive metastatic breast cancer and subsequently helping to develop and execute a randomized Phase 2/3 global trial which resulted in an FDA approval. Before joining industry, Dr. Chamberlain was a professor and academic oncologist, where he had both extensive experience as a clinician (specializing in neuro-oncology) as well as serving as Principal Investigator on multiple trials, including cooperative group, pharma sponsored as well as investigator-initiated trials. Dr. Chamberlain received his M.D. from Columbia University, College of Physicians and Surgeons and completed residencies/fellowships in pediatrics, neurology and neuro-oncology at the University of California, Los Angeles and the University of California, San Francisco. He has authored more than 500 scientific publications in major journals.
Senior Director, Facilities Operations
Larry Garrido joined Pionyr Immunotherapeutics in November 2018 as Sr. Director, Facilities Operations. Prior to Pionyr, Mr. Garrido was the Sr. Director, Facilities Operations at Relypsa, Inc., which was acquired by Galenica in September 2016. Prior to joining Relypsa, Mr. Garrido was the Associate Director, Operations at KAI Pharmaceuticals, where he oversaw Facilities, Purchasing, EH&S and IT activities. After KAI’s acquisition by Amgen in July 2012, Mr. Garrido remained with Amgen until December 2012 to assist in the transition before starting at Relypsa. Before joining KAI, Mr. Garrido started his career in the biopharma industry as Manager, materials in December 1998 at COR Therapeutics, which was acquired by Millennium Pharmaceuticals in December 2001. While at COR, along with managing the shipment of clinical supplies and import of API for manufacturing, Mr. Garrido also played a vital role in supporting Facilities, EH&S and purchasing functions.
Evan Greger, MBA, MSc
Senior Vice President and Chief Technical Officer
Evan Greger joined Pionyr Immunotherapeutics in June 2018 and has over 20 years of experience in leadership roles in biopharmaceutical companies, with research, process/product development, manufacturing, CMC, and regulatory expertise. Prior to Pionyr, he served as VP, CMC and Process Development for Cell Design Labs / Kite Pharma, where he worked on next generation CAR T therapy, and was the Senior Director, Manufacturing Process Sciences at Juno Therapeutics, where he advanced CAR T therapies into the EU with Celgene and into China with JW Therapeutics. Prior to this role, Mr. Greger was Global Head of Manufacturing Sciences and Technology for Biopharmaceutical Operations with Novartis in Basel, Switzerland. He previously held senior positions with Amgen, where he led Enbrel commercialization, advanced the oncology and biosimilar pipeline, and at Sanofi Pasteur and Alpharma, where he advanced vaccine development and commercialization. Mr. Greger holds an MBA from Seattle University and a MSc from University of Washington.
Lynnae Jackson, MBA
Senior Director, Clinical Operations
Lynnae Jackson joined Pionyr in August 2020, bringing over 30 years’ clinical operations leadership within the biotechnology industry. Prior to joining Pionyr, through her consulting business, Ms. Jackson provided her clinical operations expertise to BeiGene and Pionyr. Before that, she served as Senior Director of Clinical Operations at Agensys, Inc., a subsidiary of Astellas Pharma, where she oversaw the management of clinical development of multiple antibody products to novel targets from Phase 1 First-in-Human studies through Phase 2 Proof-of-Concept studies for multiple products. During Ms. Jackson’s tenure at Agensys, her work was instrumental in the FDA granting accelerated approval for Padcev in the treatment of advanced Urothelial Cancer. Ms. Jackson’s prior positions in industry included Senior Director at Amgen, Inc. managing various Phase 2 through Phase 4 clinical trials across multiple therapeutic areas including: Nephrology, Infectious Disease, Rheumatology and Oncology. While at Amgen, she was a key member involved in the NDA for Neupogen. Ms. Jackson started her career at Genentech, Inc., working in their Endocrinology group. She has co-authored more than 20 scientific publications. Ms. Jackson holds a BS in Biology from San Francisco State University and an Executive MBA from Pepperdine University.
Vice President, Quality
Irina Kasatkina joined Pionyr in July 2021, bringing over 20 years of experience in leadership roles for quality and compliance functions. Ms. Kasatkina has extensive experience with a wide range of quality systems and a track record of successful interactions with regulatory agencies.
Prior to Pionyr, she served as VP of Quality for Dermira, where she led the organization encompassing Quality Operations, Quality Control, Quality Systems, Compliance, and Inspection Management. During her tenure at Dermira, Ms. Kasatkina enabled phase-appropriate and risk-based controls for commercial and clinical products and maintained a high level of cGMP compliance through the effective monitoring and reporting of key metrics. Before joining Dermira, Ms. Kasatkina worked at Genentech, holding roles of increasing responsibilities in quality, supply chain, and manufacturing. She led various quality functions, including Supply Chain Quality, Change Control, Document Control, Investigation Management, Lot Release, and Complaint Management. She also served as a Head of Logistics Management and Trade Compliance.
Ms. Kasatkina holds a M.S. Summa cum laude in Engineering and Technology of Food Industry from National Academy of Food Technologies, in Odessa, Ukraine.
Alicia Levey, PhD
Senior Vice President, Chief Business Officer and Head of Portfolio Strategy
Alicia Levey joined Pionyr in July 2019 and leads business development, business operations, portfolio strategy, and program management in addition to managing intellectual property and legal functions. Prior to Pionyr, Dr. Levey served as the Chief Business Officer of Tempest Therapeutics and was a key contributor to establishing the company outside of Inception Sciences and raising $70M in venture funding. Leading up to the spin-out of Tempest, she was VP of Business Development at Inception Sciences, a small molecule drug discovery company formed in collaboration with Versant Ventures, a global venture capital firm focused primarily on early stage investing and biotechnology company creation. Dr. Levey served as a member of the Versant Ventures Investment Team for over 8 years, most recently as an Operating Principal. While at Versant, she was a key contributor to multiple Series A investments (Novira, Audentes, Therachon among others) and business development efforts for portfolio companies. Dr. Levey worked as a Consultant, and later a Project Leader in The Boston Consulting Group. While at BCG, she focused primarily on biopharma and global health. Dr. Levey has authored several peer reviewed scientific publications and her inventions are covered in two United States Patents. Dr. Levey earned a Ph.D. in Cancer Biology from the Stanford University School of Medicine.
Yunfeng Li, PhD
Senior Director, Biostatistics
Yunfeng Li joined Pionyr in January 2021 and leads biometrics-related activities. He has over 20 years of experience in the pharmaceutical industry focused on biometrics. Prior to Pionyr, Dr. Li served as Senior Director of Biostatistics for Assembly Bioscience, working on statistical design, analysis, and reporting. Before joining Assembly, Dr. Li built and led the oncology biostatistics team at Nektar, where he worked on an EU MAA submission for breast cancer and immunotherapy development on solid tumors. Prior to Nektar, Dr. Li held senior research positions in biostatistics at Pharmacyclics, Cerexa, Shire, and Wyeth where he was involved in multiple regulatory submissions and all phases of clinical trials across multiple therapeutic areas including oncology, hematology, infectious disease, and central nervous system diseases. Dr. Li received a Ph.D. in Mathematics from the University of Science and Technology of China.
Linda Liang, PhD
Vice President, Protein Sciences
Linda Liang has over 15 years of experience in the biopharmaceutical industry focused on developing biologic therapeutics for multiple targets. She joined Pionyr Immunotherapeutics in 2019 to lead the Protein Sciences and Antibody Generation group. Prior to Pionyr, Dr. Liang held senior research positions in protein sciences and antibody discovery at Bristol-Myers Squibb, Merck, Schering-Plough, and Organon where she made significant contributions to biologics discovery efforts in metabolic diseases, autoimmune and inflammatory diseases, and immune-oncology. Dr. Liang received a Ph.D. in Immunology from the University of California, Berkeley.
Senior Director, Clinical Operations
Isabel Luther joined Pionyr Immunotherapeutics in June 2019, bringing more than 25 years of experience in clinical drug development, including over 20 years dedicated to clinical operations in oncology. Before joining Pionyr, Ms. Luther served as VP, Clinical Operations in a consulting role at Naked Biome, Inc. Prior to joining Naked Biome, Ms. Luther was Sr. Clinical Program Manager, Clinical Operations, at Gilead Sciences. At Gilead, she oversaw development of multiple, concurrent assets in oncology, as well as managed the respective functional resources, at various phases of clinical research. Prior to Gilead, Ms. Luther served in supervisory roles at organizations including Onyx Pharmaceuticals (acquired by Amgen), Medivation (acquired by Pfizer), and Sugen (acquired by Pharmacia). Early in her career, Ms. Luther worked for CROs monitoring clinical trials in the field, beginning with her biopharmaceutical research internship at Corning-Besselaar (now Covance, Inc.). She holds a B.A. in Psychology from the University of California, Berkeley.
Senior Vice President and Chief Financial Officer
Monte Montgomery joined Pionyr Immunotherapeutics in August 2017 as Chief Financial Officer. Prior to Pionyr, Mr. Montgomery served as VP, Finance and Chief Accounting Officer at Relypsa, Inc. which was acquired by Galenica in September 2016. Prior to joining Relypsa, Mr. Montgomery was the Executive Director, Finance at KAI Pharmaceuticals where he oversaw Finance, Facility, Purchasing and IT activities until KAI’s acquisition by Amgen in July 2012. Before joining KAI, Mr. Montgomery was Director, SEC Reporting at Exelixis, Inc. where he was a key contributor in various equity offerings, collaborations, and other fund-raising activities. Earlier in his career, Mr. Montgomery was an audit professional in Ernst & Young life sciences practice. He holds a B.A. in Business Economics from the University of California, Santa Barbara and he is a certified public accountant (inactive).
Leonard Reyno, MD
Senior Vice President and Chief Medical Officer
Prior to joining Pionyr, Leonard Reyno was EVP and Chief Medical Officer at ORIC Pharmaceuticals leading the introduction of their first product candidate into human trials. Before that, he served as Senior Vice President and Chief Medical Officer at Agensys, a subsidiary of Astellas Pharma, where he led clinical stage development of multiple antibody products to novel targets through clinical proof of concept of multiple products. Dr. Reyno’s prior positions in industry included Global Medical Director for Taxotere/Breast cancer at Aventis, Medical Director and Lead Clinical Scientist for Herceptin at Genentech and Senior Director of Oncology at Cytokinetics. Before joining industry, Dr. Reyno was an academic oncologist, where he had both extensive experience as a clinician (especially in breast and genitor-urinary malignancy) as well as serving as Principal Investigator on multiple trials with the National Cancer Institute of Canada. Dr. Reyno was Head of Medical Oncology and the Oncology Clinical Research Unit at Dalhousie University from 1999-2003, and previously Associate Professor of Medicine at McMaster University from 1993-1999. Dr. Reyno received his M.D. from McMaster University in 1986. He completed fellowships in internal medicine and medical oncology at McMaster and further training in drug development at the University of Maryland at Baltimore as the McEachern Fellow of the National Cancer Institute of Canada from 1991-1993. He has authored more than 25 scientific publications in major journals.
Lisa Stemmerich, MBA
Vice President, Human Resources
Lisa Stemmerich joined Pionyr in May 2016, bringing 25 years’ human resources leadership within the life sciences and agricultural biotechnology industries. Prior to Pionyr, through Ms. Stemmerich’s executive HR consulting practice, she acted as VP, Human Resources for a variety of drug discovery companies including 4D Molecular Therapeutics, Inc., Antiva Biosciences, Armetheon, Inc., Labrys Biologics, Inc. acquired by Teva Pharmaceuticals, Inc. and KAI Pharmaceuticals, Inc. acquired by Amgen, Inc. Prior to providing executive Human Resources consulting, Ms. Stemmerich led the HR function at Exelixis, Inc. During Ms. Stemmerich’s tenure at Exelixs, Inc. she was instrumental in the growth and organization of the company as Exelixis completed an initial public offering and grew from 170 to over 600 employees located domestically and abroad. Prior to Exelixis, Inc., Ms. Stemmerich was Director, Human Resources at Calgene, Inc., an agricultural biotechnology company acquired by Monsanto Company, and then by Pharmacia Company. She holds a BS in Business Administration from California State University, Sacramento and an MBA from University of California, Davis.
Carol Gallagher, PharmD
Dr. Gallagher joined NEA as a Partner in October, 2014. She is a proven entrepreneur, operator and, more recently, investor with nearly 30 years of experience in commercial, drug development and business development roles at large and small pharmaceutical companies. From 2008-2011, Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. After the sale of Calistoga Pharmaceuticals, she spent several years serving as an independent director on multiple biopharma company boards before pursuing a career in venture capital. In addition to serving as a director at Pionyr, she currently serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, Cleave Biosciences and AnaptysBio.
Rishi Gupta, JD
Rishi Gupta is a Partner at OrbiMed. Prior to that, he was a healthcare investment banker at Raymond James & Associates, served as manager of corporate development at Veritas Medicine and was a summer associate at Wachtell, Lipton, Rosen & Katz. In addition to Pionyr, Rishi serves or has served on the boards of Turnstone Biologics, EnLiven Therapeutics, NeuroPace, Verona Pharma, Avitide, Modis Therapeutics, Symbiomix Therapeutics, Dimension Therapeutics, ChemoCentryx and Sientra. He has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae and ORIC Pharmaceuticals. Rishi earned a J.D. from the Yale Law School and an A.B. degree magna cum laude in biochemical sciences from Harvard College.
Steven P. James
President and CEO, Pionyr Immunotherapeutics
Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Steve is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Allakos Inc and Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).
Regina Salvat, PhD
Prior to joining Sofinnova in 2020, Regina was an Associate Director of Strategy and Corporate Development at Rubius Therapeutics. Before joining Rubius, Regina supported a range of bio-pharmaceutical companies as a Strategy Consultant at Huron Consulting Group (formerly, The Frankel Group). While in graduate school at Dartmouth, Regina studied Protein Engineering. Her work as a graduate student was later commercialized in a company, Stealth Biologics. Prior to graduate school, Regina worked as a Senior Associate Scientist of Cell Line Development within Bioprocess R&D at Pfizer.
Regina received her PhD from the Thayer School of Engineering at Dartmouth College, where she was a Clare Boothe Luce Fellow and an Innovation Fellow. Regina also holds a B.S. in Biological Engineering and M.Eng. in Biomedical Engineering, from Cornell University.
William Grossman, MD, PhD
SVP, Oncology Clinical Development & Therapeutic Area Head, Gilead Sciences
Bill joined Gilead Sciences in July 2021 as the Senior Vice President of Oncology Clinical Development to oversee the company’s Oncology portfolio and collaboration programs. Prior to that, he held Chief Medical Officer roles at Arcus Biosciences and Bellicum Pharmaceuticals. He has held additional leadership roles at Merck, Baxter, Biothera, AbbVie and Genentech/Roche. Bill has more than 25 years of experience in oncology, having begun his career as a practicing hematologist/oncologist with expertise in bone marrow transplants before moving into the biopharmaceutical industry. At the Children’s Hospital of Wisconsin/Medical College of Wisconsin, he was Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetics and Director of the Bone Marrow Transplant Division for the Immunodeficiency Transplant Program.
Bill received his MD and PhD in Immunology from Washington University School of Medicine’s Medical Scientist Training Program and completed his medical and post-doctoral training in the Divisions of Pediatrics and Medicine at Washington University School of Medicine.
Mike Ross, PhD
SV Health Investors
Mike Ross’ career spans over 15 years in venture capital, which followed 21 years in senior operating executive roles for leading biotechnology companies. He joined SV Health Investors as a Venture Partner in 2001 and became a Managing Partner in 2002. Mike was the tenth employee at Genentech, where he worked for 13 years. He served as Genentech team leader for the Humulin® Roferon®, Protropin® programs and was Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. He then started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. Mike was the Founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera (now Viacyte). He was also Managing Partner in Didyma, LLC, a biotechnology management consulting firm. Mike served on the boards of Carta Proteomics, Epimmune, Genencor, MetaXen, and Xenova.
Mike received his PhD in Chemistry from Caltech and went on to do his post-doctoral work at Harvard. He serves on the Board of the Thayer School of Engineering (Dartmouth College).
Max Krummel, PhD (Chair)
Professor, Department of Pathology, UCSF
Dr. Krummel is a Professor and the Robert E. Smith Endowed Chair in Experimental Pathology at UCSF. He studies mechanisms that regulate T cell response and immune function using cutting-edge real-time imaging methods. As a graduate student, he developed expertise in the generation and use of monoclonal antibodies targeted to costimulatory and inhibitory molecules on T cells. He generated antibodies to CTLA-4, which identified an inhibitory pathway of T cell regulation and also could be used to trigger or block that pathway. This approach led to the development of human antibodies of the same type, a therapy now named ‘ipilimumab’, which is FDA approved and widely used for treatment of melanoma and other cancers.
Dr. Krummel’s lab focuses on understanding how immune systems, collections of cells in complex tissues, work. The use of fluorescent proteins and real-time imaging enable the examination of information processing by the immune system. These approaches reveal how motile immune cells ‘search’ their environment for critical information and characterize specific phagocytes in the tumor microenvironments as primary players in transmitting signals to lymphocytes and regulating disease outcome.
Dr. Krummel earned his doctorate at UC Berkeley and did postdoctoral fellowships at Stanford University and the Walter and Eliza Hall Institute in Melbourne, Australia.
Chloe Atreya, MD, PhD
Assistant Clinical Professor, Department of Medicine, UCSF
Dr. Atreya is a physician scientist in the Gastrointestinal Oncology Group at UCSF. She received an MD and PhD in Pharmacology from Yale University in 2005. After completing her internal medicine residency at the University of Washington, she joined UCSF as a Fellow in the Division of Hematology/Oncology. She continued as a Postdoctoral Scholar in the laboratory of Dr. Kevan Shokat. Dr. Atreya joined the UCSF faculty in 2013. In 2014, she attained certification in Advanced Training in Clinical Research and she has since served as the Principal Investigator on several clinical trials.
Her research focuses on the interplay of molecular markers and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment. Dr. Atreya is the recipient of numerous awards, including a NIH/NCI K08 Career Development Award for targeting of aberrant signaling in patient-derived colorectal cancer models and a 2018 R21 award to study the impact of the gut microbiome on metabolism or oral chemotherapy.
Miriam Merad, MD, PhD
Professor of Oncological Science, Medicine and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute, Mount Sinai School of Medicine
Dr. Merad is the director of both the Precision Immunology Institute at Mount Sinai School of Medicine and the Mount Sinai Human Immune Monitoring Center (HIMC). She also co-directs the Cancer Immunology Program at the Mount Sinai Tisch Cancer Institute. Dr. Merad’s laboratory studies the contribution of macrophages and dendritic cells to cancer and inflammatory disease in mice and humans. Dr. Merad’s pioneering work mapping the regulatory network of dendritic cells (DCs) resulted in identification of a lineage of DC, the CD103+ DC, that is now considered a key target to improve antiviral and antitumor immunity. These insights, along with other significant discoveries, are now being used to develop novel macrophage and dendritic cell-specific targets for the treatment of cancer and inflammatory diseases.
Dr. Merad has authored more than 160 primary papers and reviews in high profile journals and receives funding from the National Institutes of Health (NIH) for her research on innate immunity and its contribution to human disease. Dr. Merad obtained her MD at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her PhD in immunology in collaboration between Stanford University and University of Paris VII.
Stephen Hodi, MD
Director of the Melanoma Center and the Center for Immuno-Oncology, Dana-Farber Cancer Institute
Dr. Stephen Hodi is the Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber / Brigham and Women’s Cancer Center, the Sharon Crowley Martin Chair in Melanoma at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Dr. Hodi is a graduate of Harvard University and Cornell University Medical College. He completed his postdoctoral training in Internal Medicine at the Hospital of the University of Pennsylvania and his medical oncology training at Dana-Farber cancer Institute, where he joined the faculty in 1998. His research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the American Association for Cancer Research, the Eastern Cooperative Oncology Group Melanoma Committee, the Society for Immunotherapy of Cancer, the European Academy of Tumor Immunology and a founding member of the Society for Melanoma Research.
Dr. Hodi is an internationally recognized leader in the development of immune therapy and melanoma therapeutics. In particular, he is known for the clinical development of immune checkpoint inhibitors. His clinical investigation efforts have pioneered the use of immune checkpoint blockade and combinatorial approaches to treat cancer. His publications include articles in the Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and the New England Journal of Medicine.